| dc.creator |
AFŞAR, Barış |
|
| dc.creator |
Kanbay, Mehmet |
|
| dc.creator |
Karahan, Salih |
|
| dc.date |
2018-07-31T21:00:00Z |
|
| dc.date.accessioned |
2020-10-06T09:26:52Z |
|
| dc.date.available |
2020-10-06T09:26:52Z |
|
| dc.identifier |
145844b2-9114-4239-b3b6-d50b643672f4 |
|
| dc.identifier |
10.1093/ckj/sfy044 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/145844b2-9114-4239-b3b6-d50b643672f4/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/53914 |
|
| dc.description |
Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is related with impaired endothelial function and poor outcomes in chronic kidney disease (CKD) patients. In addition, oxidative stress and inflammation are also a common problemin CKD patients, and both have an important role in the development and progression of atherosclerosis and increased cardiovascular events in CKD. Ascorbic acid might be a promising agent in CKD for improving outcome by decreasing oxidative stress and ADMA levels. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Ascorbic acid: a promising agent in chronic kidney disease? |
|
| dc.type |
info:eu-repo/semantics/article |
|